• Recordati disclosed a co-investment and shareholders’ agreement signed October 28, 2026, by Respighi TopCo, CVC Investor, GBL Investor, Arisca and Bullitt.
• Arisca’s investment through Bullitt provides a 3.5% ordinary-share stake in Respighi TopCo, which indirectly controls the drugmaker.
• Bullitt waived voting rights indefinitely and faces a 10-year transfer lockup, subject to exceptions.
• CVC Investor and GBL Investor must secure Andrea Recordati a three-year board seat, initially as chairman, subject to continued indirect ownership.
• The agreement runs for up to 15 years, with earlier termination provisions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Recordati Industria Chimica e Farmaceutica S.p.A. published the original content used to generate this news brief via SDIR, the Italian regulatory disclosure system (Ref. ID: 216_173242_2026_oneinfo.pdf), on November 02, 2026, and is solely responsible for the information contained therein.